Release Date: 18/02/19 08:51 Summary: Andrew Russell appointed CEO & Managing Director Price Sensitive: Yes Download Document 162KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%